164 related articles for article (PubMed ID: 17099630)
1. Using biomarkers in drug development.
Workman P
Clin Adv Hematol Oncol; 2006 Oct; 4(10):736-9. PubMed ID: 17099630
[No Abstract] [Full Text] [Related]
2. Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development.
Takimoto CH
Eur J Cancer; 2009 Sep; 45 Suppl 1():436-8. PubMed ID: 19775662
[No Abstract] [Full Text] [Related]
3. ASCO presentations highlight value of cancer biomarkers.
Opar A
Nat Rev Drug Discov; 2008 Jul; 7(7):547-8. PubMed ID: 18591972
[No Abstract] [Full Text] [Related]
4. Ex vivo biomarkers: functional tools to guide targeted drug development and therapy.
Clark DP
Expert Rev Mol Diagn; 2009 Nov; 9(8):787-94. PubMed ID: 19895224
[TBL] [Abstract][Full Text] [Related]
5. Advances and challenges in the use of biomarkers in clinical trials.
Chabner B
Clin Adv Hematol Oncol; 2008 Jan; 6(1):42-3. PubMed ID: 18322440
[No Abstract] [Full Text] [Related]
6. Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective.
Fine BM; Amler L
Clin Pharmacol Ther; 2009 May; 85(5):535-8. PubMed ID: 19295504
[No Abstract] [Full Text] [Related]
7. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.
Park JW; Kerbel RS; Kelloff GJ; Barrett JC; Chabner BA; Parkinson DR; Peck J; Ruddon RW; Sigman CC; Slamon DJ
Clin Cancer Res; 2004 Jun; 10(11):3885-96. PubMed ID: 15173098
[No Abstract] [Full Text] [Related]
8. [Individualized anticancer therapies: which regulatory guidelines?].
Bedairia N; Marty M
Bull Cancer; 2008 Oct; 95(10):985-8. PubMed ID: 19004730
[TBL] [Abstract][Full Text] [Related]
9. From darkness to light with biomarkers in early clinical trials of cancer drugs.
Carden CP; Banerji U; Kaye SB; Workman P; de Bono JS
Clin Pharmacol Ther; 2009 Feb; 85(2):131-3. PubMed ID: 19151637
[TBL] [Abstract][Full Text] [Related]
10. Cancer biomarkers: current issues and future directions.
Jain KK
Curr Opin Mol Ther; 2007 Dec; 9(6):563-71. PubMed ID: 18041667
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers in early cancer drug development: limited utility.
Glassman RH; Ratain MJ
Clin Pharmacol Ther; 2009 Feb; 85(2):134-5. PubMed ID: 19151638
[TBL] [Abstract][Full Text] [Related]
12. Criticism of tumor response criteria raises trial design questions.
Twombly R
J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740
[No Abstract] [Full Text] [Related]
13. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
Lee JW; Figeys D; Vasilescu J
Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
[TBL] [Abstract][Full Text] [Related]
14. Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress.
Garcia VM; Cassier PA; de Bono J
Cancer Discov; 2011 Aug; 1(3):207-12. PubMed ID: 22586572
[TBL] [Abstract][Full Text] [Related]
15. The search for optimal response prediction in cancer leads to a personalized approach.
Van Cutsem E; Ciardiello F
Target Oncol; 2010 Mar; 5(1):3-4. PubMed ID: 20349283
[No Abstract] [Full Text] [Related]
16. Recent advances in clinical oncoproteomics.
Jain KK
J BUON; 2007 Sep; 12 Suppl 1():S31-8. PubMed ID: 17935275
[TBL] [Abstract][Full Text] [Related]
17. Diagnostics in cancer drug development.
Sikora K
Expert Rev Mol Diagn; 2004 Mar; 4(2):127-9. PubMed ID: 14995899
[No Abstract] [Full Text] [Related]
18. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
Le Tourneau C; Vidal L; Siu LL
Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
[TBL] [Abstract][Full Text] [Related]
19. Promises of biomarkers in drug development--a reality check.
Marrer E; Dieterle F
Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
[TBL] [Abstract][Full Text] [Related]
20. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.
O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L
Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
